サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1473664

オリゴヌクレオチド合成の世界市場：製品別、タイプ別、用途別 - 予測（～2029年）

Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligo (Primer), Reagents, Equipment), Type (Custom, Predesigned), Application (Therapeutic (Neurology, Rare), Research (PCR, Sequencing), Diagnostics) - Global Forecast to 2029
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 432 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.74円
オリゴヌクレオチド合成の世界市場：製品別、タイプ別、用途別 - 予測（～2029年）
出版日: 2024年04月26日
発行: MarketsandMarkets
ページ情報: 英文 432 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のオリゴヌクレオチド合成の市場規模は、2024年の88億米ドルから、予測期間中は17.5%のCAGRで推移し、2029年には197億米ドルの規模に成長すると予測されています。

製品別では、合成オリゴヌクレオチドの市場規が、2024年の22億米ドルから、予測期間中は17.0%のCAGRで推移し、2029年には49億米ドルの規模に成長すると予測されています。

同市場の成長は、プライマーやプローブなどの合成オリゴヌクレオチドがさまざまな研究や診断用途に使用されるようになったことなど、いくつかの要因によって牽引されています。オリゴヌクレオチド合成分野における技術の進歩は、さらに市場の成長に貢献しています。

調査範囲
調査対象年 2022-2029年
基準年 2023年
予測期間 2024-2029年
単位 金額 (米ドル)
セグメント 製品・用途・エンドユーザー・地域
対象地域 北米・欧州・アジア太平洋・ラテンアメリカ・中東&アフリカ

合成オリゴヌクレオチド向けオリゴヌクレオチド合成市場の成長は、新規オリゴヌクレオチドベースの医薬品の開発と診断における幅広い用途に焦点を当てた研究の高まりに起因：

合成オリゴヌクレオチドは、新薬開発の研究において幅広く応用されており、主にPCRやシークエンシングに使用されています。さらに、遺伝性疾患の検出に使用される診断手順やコンパニオン診断も、合成オリゴヌクレオチドの主要な応用分野の一部です。

製品別では、プライマーの部門が合成オリゴヌクレオチド市場でもっとも高い成長率を示す：

プライマーは、PCR、シークエンシング、遺伝子合成、クローニングなど幅広い用途で使用されているため、予測期間中にもっとも高い成長が見込まれています。プライマーは、遺伝子発現研究、分子診断、遺伝子解析のための標的遺伝子配列の増幅を可能にします。

治療用途別では、神経疾患の部門が2023年に最大のシェアを示す：

主要企業がDMDやSMAなどの神経疾患治療用のオリゴベースの薬剤開発に注力していることから、神経疾患の部門が2023年に最大シェアを示しました。これらの疾患の治療薬として使用されるオリゴベースの薬剤は、FDAの承認がもっとも多いです。

北米地域がもっとも高いCAGRを記録する見通し：

北米のオリゴヌクレオチド合成市場は、予測期間中にもっとも高い成長率を示すと予測されています。さまざまな希少疾患や神経疾患に対するオリゴヌクレオチドベースの治療法を開発するために、政府機関、バイオテクノロジー企業、製薬会社から提供される継続的な投資や資金調達、強力なベンチャーキャピタルエコシステムの存在、この地域における新規および代替療法に対する意識の高まりと早期採用などが、同地域市場の成長を支えるいくつかの要因です。また、北米には確立された医薬品製造インフラがあり、Danaher CorporationやThermo Fisherなどオリゴヌクレオチド合成市場の有力企業が存在することも、同地域のリーダー的地位をさらに支えています。

当レポートでは、世界のオリゴヌクレオチド合成の市場を調査し、市場概要、市場影響因子および市場機会の分析、技術・特許の動向、法規制環境、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 市場動向
  • 顧客のビジネスに影響を与える動向/ディスラプション
  • サプライチェーン分析
  • バリューチェーン分析
  • エコシステム分析
  • 技術分析
  • 価格分析
  • 特許分析
  • パイプライン分析
  • 貿易分析
  • 主な会議とイベント
  • 規制状況
  • ポーターのファイブフォース分析
  • 主なステークホルダーと購入基準
  • 主な購入基準
  • ケーススタディ分析
  • 投資/資金調達シナリオ

第6章 オリゴヌクレオチド合成市場：製品別

  • オリゴヌクレオチド系医薬品
    • オリゴヌクレオチド系医薬品市場：タイプ別
  • 合成オリゴヌクレオチド
    • 合成オリゴヌクレオチド市場：製品別
    • 合成オリゴヌクレオチド市場：タイプ別
  • 試薬・消耗品
  • 機器

第7章 オリゴヌクレオチド合成市場：用途別

  • 治療
  • 研究
    • PCR
    • シークケンシング
    • その他
  • 診断

第8章 オリゴヌクレオチド合成市場：エンドユーザー別

  • 病院
  • 製薬・バイオテクノロジー企業
  • 診断ラボ
  • CRO・CMO
  • 研究機関

第9章 オリゴヌクレオチド合成市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第10章 競合情勢

  • 主要企業の戦略/有力企業
  • 収益分析 (研究・診断用途)
  • 市場シェア分析 (研究・診断用途)
  • 収益分析 (治療用途)
  • 企業評価マトリックス：主要企業 (研究・診断用途)
  • 企業評価マトリックス：主要企業 (治療用途)
  • 企業評価マトリックス：スタートアップ/中小企業
  • 競合シナリオ
  • オリゴヌクレオチド合成市場ベンダーの評価と財務指標 (研究・診断用途)
  • オリゴヌクレオチド合成市場ベンダーの評価と財務指標 (治療用途)
  • ブランド/製品比較分析

第11章 企業プロファイル

  • 主要企業
    • DANAHER CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • MERCK KGAA
    • LGC LIMITED
    • EUROFINS SCIENTIFIC
    • AGILENT TECHNOLOGIES, INC.
    • KANEKA CORPORATION
    • MARAVAI LIFESCIENCES HOLDINGS, INC.
    • AZENTA, INC.
    • TWIST BIOSCIENCE CORPORATION
    • GENSCRIPT BIOTECH CORPORATION
  • 主要企業 (治療製品)
    • BIOGEN INC.
    • ALNYLAM PHARMACEUTICALS, INC.
    • SAREPTA THERAPEUTICS, INC.
    • ASTRAZENECA
    • ASTELLAS PHARMA INC.
    • JAZZ PHARMACEUTICALS PLC
    • NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
    • IONIS PHARMACEUTICALS, INC.
    • NOVARTIS AG
  • その他の企業
    • OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
    • BIOLEGIO BV
    • BIOLYTIC LAB PERFORMANCE, INC.
    • BIOCOMMA LIMITED
    • REVVITY, INC. (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
    • BIO-SYNTHESIS, INC.
    • CREATIVE BIOGENE
    • REPROCELL, INC. (THROUGH SUBSIDIARY BIOSERVE)

第12章 付録

目次
Product Code: BT 2680

The oligonucleotide synthesis market is projected to reach USD 19.7 billion by 2029 from USD 8.8 billion in 2024, at a CAGR of 17.5% during the forecast period. The synthesized oligonucleotide market is projected to reach USD 4.9 billion in 2029 from USD 2.2 billion in 2024, growing at a CAGR of 17.0% during the forecast period. The growth of this market is driven by several factors such as the increasing use of synthesized oligonucleotides such as primers and probes for various research and diagnostic applications. Technological advancements in the field of oligonucleotide synthesis further contribute to the growth of the market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsProduct, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The oligonucleotide synthesis market growth for synthesized oligonucleotides can be attributed to the growing research focused on the development of novel oligonucleotide-based drugs and their wide applications in diagnostic procedures."

The oligonucleotide synthesis market, based on synthesized oligonucelotides (part of product segmentation), is further segmented into primer, probes, DNA Oligos, RNA Oligos, Other synthesized oigonucelotides. Synthesized oligonucelotides have a wide application in research for novel drug development and are mainly used in PCR and sequencing. Additionlly, diagnostic procedures used for detection of genetic disorders, companion diagnostics are also few of the major application areas for synthesized oligonucelotides.

"The primers segment will grow at the highest rate in the synthesized oligos market, by product."

By Product, synthesized oligonucelotide maket is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos including BNA & LNA oligos. Primers are expected to grow at the highest rate during the forecasted period owing to the extensive use of primers in a wide range of applications such as PCR, sequencing, gene synthesis and cloning. Primers allow aplification of target gene sequences for gene expression studies, molecular diagnostics and genetic analysis.

"By therapeutic application, the neurological disease segment accounted for the largest share of the oligonucleotide synthesis market in 2023."

The therapeutic application segment is segmented by disease type into neurological, rare and other diseases. In 2023, neurological disease segment accounted for the largest share of this segment as major companies are focusing on the development of oligo-based drugs for the treatment of neurological diseases such as DMD and SMA. Oligo based drugs that are used as therapies for these disorders have most FDA approvals.

"North American region is expected to register a highest CAGR in the oligonucleotide synthesis market."

The market for oligonucleotide synthesis in North America is estimated to grow at the highest rate during the forecast period. Ongoing investments and funding provided by various government bodies, biotechnology and pharmaceutical companies to develop oligonucelotide based therapies for various rare and neurological disease, presence of strong venture capital ecosystem, growing awareness and early adoption of novel and alternate therapies in this region are few factors that support thr growth of this regional market. North America also has the established pharmceutical manufacturing infrastructure and the presence of the promnient players of the oligonucleotide synthesis market such as Danaher Corporation and Thermo Fisher among other which futher supports the leadership position of this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side - 30%
  • By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
  • By Region: North America -35%, Europe - 25%, Asia-Pacific -15%, Latin America -10%, Middle East- 10%, Africa- 5%

List of Companies Profiled in the Report Offering Products For Research and Diagnostic Applications:

  • Danaher Corporation (US)
  • Thermo Fisher Scientific Inc. (US)
  • Merck KGaA (Germany)
  • Eurofins Scientific (Luxembourg)
  • LGC Limited (UK)
  • Agilent Technologies, Inc. (US)
  • Kaneka Corporation (Japan)
  • Maravai Lifesciences holdings, Inc. (US)
  • Azenta, Inc. (US)
  • Twist Bioscience Corporation (US)
  • Genscript Biotech Corporation (US)

List of Companies Profiled in the Report Offering Products For Therapeutic Applications:

  • Biogen Inc. (US)
  • Alnylam Pharmaceuticals, Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Astrazeneca (UK)
  • Astellas Pharma Inc. (Japan)
  • Jazz Pharmaceuticals Plc (Ireland)
  • Nippon Shinyaku, Co. Ltd. (Japan)
  • Ionis Pharmaceuticals, Inc. (US)
  • Novartis AG (Switzerland)

Note: Above list is inexhaustive

Research Coverage:

This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market's size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oligonucleotide synthesis market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (e.g., Increasing use of synthesized oligos in therapeutic and diagnostic applications, Technological advancements), restraints (e.g., complexities associated with oligonucleotide-based drugs), opportunities (e.g., increasing pharma R&D investments in emerging economies), and challenges (e.g., lack of standard regulations) are influencing the growth of the oligonucleotide synthesis market.
  • Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide synthesis market across varied regions.
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
  • Pipeline Analysis: Comprehensive information about products under clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), among others offering products for research & diagnostic applications and Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US) among others offering products for therapeutic applications.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION
    • FIGURE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: REGIONAL SEGMENTATION
    • 1.4.1 YEARS CONSIDERED
    • 1.4.2 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT: OLIGONUCLEOTIDE SYNTHESIS MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
    • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2023
    • FIGURE 7 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2023
    • FIGURE 8 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH AND DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
    • FIGURE 9 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2023
    • FIGURE 10 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.1 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
    • FIGURE 11 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH FORECAST
    • FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024-2029
    • FIGURE 13 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET (THERAPEUTIC APPLICATIONS), 2024-2029
    • FIGURE 14 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
  • 2.5 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 15 DATA TRIANGULATION METHODOLOGY
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ANALYSIS
  • 2.8 IMPACT OF RECESSION ON OLIGONUCLEOTIDE SYNTHESIS MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2024-2029 (USD MILLION)
    • FIGURE 19 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET

4 PREMIUM INSIGHTS

  • 4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
    • FIGURE 20 INCREASING USE OF SYNTHESIZED OLIGOS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2023)
    • FIGURE 21 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • 4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2024 VS. 2029
    • FIGURE 22 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2029
  • 4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2023
    • FIGURE 23 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 24 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of synthesized oligos in therapeutic and diagnostic applications
    • TABLE 4 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016-2023)
      • 5.2.1.2 Technological advancements
      • 5.2.1.3 Growing government investments in life science research and synthetic biology
      • 5.2.1.4 Growing focus on precision/personalized medicine
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complexities associated with therapeutic oligonucleotides
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing R&D investments by key players in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of standard regulations
      • 5.2.4.2 Delivery of oligonucleotide drugs to specific targets
  • 5.3 MARKET TRENDS
    • 5.3.1 FOCUS ON DEVELOPING NEW DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
    • 5.3.2 FOCUS ON DEVELOPING NEW TECHNOLOGIES FOR SUSTAINABLE AND LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
    • 5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
    • TABLE 5 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
    • 5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL AND RARE DISEASES
    • TABLE 6 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR OLIGONUCLEOTIDE MANUFACTURERS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • FIGURE 27 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 28 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 29 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Solid-phase synthesis
      • 5.8.1.2 Liquid-phase synthesis
      • 5.8.1.3 Enzymatic oligo synthesis
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Polymerase chain reaction (PCR)
      • 5.8.2.2 Next-generation sequencing
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Clustered regularly interspaced short palindromic repeats (CRISPR)
  • 5.9 PRICING ANALYSIS
    • TABLE 7 INDICATIVE PRICING OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
    • TABLE 8 AVERAGE SELLING PRICE FOR MAJOR OLIGONUCLEOTIDE-BASED DRUGS
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENTS FILED, BY DOCUMENT TYPE, 2012-2023
    • FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012-DECEMBER 2023)
    • TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.11 PIPELINE ANALYSIS
    • FIGURE 31 NUMBER OF ONGOING CLINICAL TRIALS FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COMPANY
    • FIGURE 32 NUMBER OF ESTIMATED LAUNCHES, 2024-2028
    • TABLE 10 OLIGONUCLEOTIDE-BASED DRUGS IN CLINICAL PIPELINE
  • 5.12 TRADE ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 REGULATORY ANALYSIS
    • 5.14.2 REGULATORY BODIES
    • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.15.1 DEGREE OF COMPETITION
    • 5.15.2 BARGAINING POWER OF SUPPLIERS
    • 5.15.3 BARGAINING POWER OF BUYERS
    • 5.15.4 THREAT OF SUBSTITUTES
    • 5.15.5 THREAT OF NEW ENTRANTS
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.16.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 5.16.2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS
  • 5.17 KEY BUYING CRITERIA
    • 5.17.1 BUYING CRITERIA OF END USERS FOR SYNTHESIZED OLIGONUCLEOTIDE PRODUCTS
    • 5.17.2 BUYING CRITERIA FOR SYNTHESIZED OLIGONUCLEOTIDES, BY END USER
    • 5.17.3 BUYING CRITERIA OF HOSPITALS FOR OLIGONUCLEOTIDE THERAPEUTIC PRODUCTS
    • 5.17.4 BUYING CRITERIA FOR OLIGONUCLEOTIDE-BASED THERAPEUTIC PRODUCTS BY HOSPITALS
  • 5.18 CASE STUDY ANALYSIS
    • 5.18.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
    • 5.18.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
    • 5.18.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
  • 5.19 INVESTMENT/FUNDING SCENARIO

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • 6.2 OLIGONUCLEOTIDE-BASED DRUGS
    • TABLE 19 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 21 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 24 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 25 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT, 2022-2029 (NUMBER OF VIALS)
    • 6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
    • TABLE 27 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
      • 6.2.1.1 Antisense oligonucleotide-based drugs
        • 6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
    • TABLE 28 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
    • TABLE 29 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 34 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 35 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.2.1.2 siRNA oligonucleotide-based drugs
        • 6.2.1.2.1 Large pipeline of products to favor market growth
    • TABLE 36 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
    • TABLE 37 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 38 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 39 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 41 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 43 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.2.1.3 Other oligonucleotide-based drugs
    • TABLE 44 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS
    • TABLE 45 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 46 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 47 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 51 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 SYNTHESIZED OLIGONUCLEOTIDES
    • TABLE 52 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 53 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • 6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
      • 6.3.1.1 Primers
        • 6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
    • TABLE 60 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 61 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 64 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 65 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.3.1.2 Probes
        • 6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
    • TABLE 67 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.3.1.3 DNA oligonucleotides
        • 6.3.1.3.1 Diverse usage of DNA oligos to support market growth
    • TABLE 74 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 75 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 79 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 80 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.3.1.4 RNA oligonucleotides
        • 6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
    • TABLE 81 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 82 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 83 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 85 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 86 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 87 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.3.1.5 Other synthesized oligonucleotides
    • TABLE 88 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 89 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 90 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    • TABLE 95 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
      • 6.3.2.1 Custom oligonucleotides
        • 6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
    • TABLE 96 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 98 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 101 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 102 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
      • 6.3.2.2 Predesigned oligonucleotides
        • 6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
    • TABLE 103 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 104 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 107 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 108 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 109 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 REAGENTS & CONSUMABLES
    • 6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
    • TABLE 110 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 111 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 114 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 115 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.5 EQUIPMENT
    • 6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET
    • TABLE 117 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 124 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 7.2 THERAPEUTIC APPLICATIONS
    • TABLE 125 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 126 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 127 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 129 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 130 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 131 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • 7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    • TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
      • 7.2.1.1 Neurological disorders
        • 7.2.1.1.1 Growing research on use of oligonucleotide-based drugs for treatment of DMD and SMA to promote market growth
    • TABLE 133 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 134 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 135 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 137 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 138 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
      • 7.2.1.2 Rare diseases
        • 7.2.1.2.1 High specificity and efficacy of oligo-based drugs against rare diseases to support growth
    • TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
      • 7.2.1.3 Other diseases
    • TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 RESEARCH APPLICATIONS
    • TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 155 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 156 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 157 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 158 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 159 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 160 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 161 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • 7.3.1 PCR
      • 7.3.1.1 Increasing use of PCR in molecular biology research to drive market growth
    • TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2022-2029 (USD MILLION)
    • 7.3.2 SEQUENCING
      • 7.3.2.1 Advancements in sequencing technologies and low cost of DNA sequencing to boost growth
    • TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • 7.3.3 OTHER RESEARCH APPLICATIONS
    • TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 DIAGNOSTIC APPLICATIONS
    • 7.4.1 INCREASING DEMAND FOR RELIABLE, SPECIFIC, AND FAST METHODS FOR DETECTION OF VARIOUS DISEASES TO SUPPORT GROWTH
    • TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 8.2 HOSPITALS
    • 8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET GROWTH
    • TABLE 191 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 192 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 193 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 195 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 196 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 197 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE GROWTH
    • TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 DIAGNOSTIC LABORATORIES
    • 8.4.1 GROWING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL GROWTH
    • TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
    • 8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES PROVIDED BY CROS & CMOS TO FAVOR MARKET GROWTH
    • TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.6 ACADEMIC RESEARCH INSTITUTES
    • 8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET GROWTH
    • TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 33 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
    • TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 228 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 229 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 230 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 231 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 232 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 233 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 Government initiatives and strategic developments by major players to drive market growth
    • TABLE 236 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 237 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 238 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 239 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 240 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 241 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 242 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Strong research infrastructure and availability of funding to support market growth
    • TABLE 244 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 245 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 246 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 247 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 248 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 249 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 250 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.2.3 NORTH AMERICA: RECESSION IMPACT
  • 9.3 EUROPE
    • FIGURE 34 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
    • TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 253 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 254 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 255 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 256 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 257 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 258 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Government and private funding towards health research to support market growth
    • TABLE 261 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 262 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 263 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 264 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 265 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 266 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 267 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Strategic collaborations and partnerships between key market players to favor market growth
    • TABLE 269 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 270 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 271 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 272 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 273 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 274 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 275 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Government initiatives to strengthen R&D activities and growing awareness to propel market growth
    • TABLE 277 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 278 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 279 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 280 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 281 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 282 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 283 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Increasing research spending and presence of major pharmaceutical and biotechnology companies to drive market
    • TABLE 285 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 286 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 287 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 288 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 289 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 290 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 291 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Research and expansion initiatives to propel market growth
    • TABLE 293 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 294 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 295 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 296 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 297 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 298 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 299 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 301 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 302 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 303 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 304 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 305 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 306 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 307 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.3.7 EUROPE: RECESSION IMPACT
  • 9.4 ASIA PACIFIC
    • TABLE 309 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 310 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 311 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 312 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 313 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 314 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 315 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 Expansion of major biotechnology and pharmaceutical companies in China to boost market
    • TABLE 318 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 319 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 320 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 321 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 322 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 323 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 324 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Growing research initiatives and strategic developments to drive market growth in Japan
    • TABLE 326 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 327 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 328 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 329 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 330 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 331 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 332 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Strong initiatives to develop bioclusters and increasing adoption of genomic technologies to aid market growth
    • TABLE 334 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 335 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 336 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 337 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 338 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 339 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 340 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Increasing government initiatives and research funding to support market growth
    • TABLE 342 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 343 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 344 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 345 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 346 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 347 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 348 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.5 SOUTH KOREA
      • 9.4.5.1 Growing research activities and strategic expansions in field of oligonucleotide synthesis to propel market growth
    • TABLE 350 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 351 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 352 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 353 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 354 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 355 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 356 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.6 REST OF ASIA PACIFIC
    • TABLE 358 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 359 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 360 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 361 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 362 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 363 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 364 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.4.7 ASIA PACIFIC: RECESSION IMPACT
  • 9.5 LATIN AMERICA
    • TABLE 366 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 367 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 368 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 369 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 370 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 372 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.5.1 BRAZIL
      • 9.5.1.1 Availability of major oligo-based therapies to support market growth
    • TABLE 375 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 376 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 377 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 378 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 379 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 380 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 381 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.5.2 MEXICO
      • 9.5.2.1 Growing adoption of NGS technology and increasing research and awareness towards oligonucleotide-based therapies to support growth
    • TABLE 383 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 384 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 385 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 386 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 387 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 388 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 389 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.5.3 ARGENTINA
      • 9.5.3.1 Increase in research collaborations and government support to boost market growth
    • TABLE 391 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 392 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 393 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 394 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 395 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 396 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 397 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.5.4 REST OF LATIN AMERICA
    • TABLE 399 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 400 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 401 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 402 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 403 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 404 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 405 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.5.5 LATIN AMERICA: RECESSION IMPACT
  • 9.6 MIDDLE EAST
    • TABLE 407 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 408 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 409 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 410 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 411 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 412 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 413 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.6.1 GCC COUNTRIES
    • TABLE 416 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 417 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 418 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 419 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 420 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 421 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 422 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 9.6.1.1 Saudi Arabia (KSA)
        • 9.6.1.1.1 Increasing focus on research and government support to propel market growth
    • TABLE 425 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 426 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 427 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 428 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 429 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 430 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 431 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 9.6.1.2 United Arab Emirates (UAE)
        • 9.6.1.2.1 Government-driven initiatives and investments to boost market growth
    • TABLE 433 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 434 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 435 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 436 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 437 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 438 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 439 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 440 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 9.6.1.3 Rest of GCC Countries
    • TABLE 441 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 442 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 443 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 444 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 445 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 446 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 447 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 448 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.6.2 REST OF MIDDLE EAST
    • TABLE 449 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 450 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 451 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 452 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 453 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 454 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 455 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.6.3 MIDDLE EAST: RECESSION IMPACT
  • 9.7 AFRICA
    • 9.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
    • TABLE 457 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 458 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 459 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 460 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 461 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • TABLE 462 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2022-2029 (USD MILLION)
    • TABLE 463 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 9.7.2 AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 KEY PLAYERS STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021-2024
    • 10.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2021-2024
  • 10.3 REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    • FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2021-2023
  • 10.4 MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    • FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH AND DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2023
    • TABLE 465 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION
  • 10.5 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS)
    • FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2021-2023
    • FIGURE 38 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2023
    • TABLE 466 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): DEGREE OF COMPETITION
  • 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
    • 10.6.1 STARS
    • 10.6.2 EMERGING LEADERS
    • 10.6.3 PERVASIVE PLAYERS
    • 10.6.4 PARTICIPANTS
    • FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH AND DIAGNOSTIC APPLICATIONS), 2023
  • 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
    • 10.7.1 STARS
    • 10.7.2 EMERGING LEADERS
    • 10.7.3 PERVASIVE PLAYERS
    • 10.7.4 PARTICIPANTS
    • FIGURE 40 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2023
    • 10.7.5 COMPANY FOOTPRINT ANALYSIS
    • FIGURE 41 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT
    • TABLE 467 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT
    • TABLE 468 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT
    • TABLE 469 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH AND DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT
    • FIGURE 42 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): COMPANY FOOTPRINT
    • TABLE 470 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): REGIONAL FOOTPRINT
    • TABLE 471 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): PRODUCT FOOTPRINT
    • TABLE 472 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT
  • 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 10.8.1 PROGRESSIVE COMPANIES
    • 10.8.2 RESPONSIVE COMPANIES
    • 10.8.3 DYNAMIC COMPANIES
    • 10.8.4 STARTING BLOCKS
    • FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2023
    • 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • TABLE 473 DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 474 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT APPROVALS
    • TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2021-FEBRUARY 2024
    • TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2021-FEBRUARY 2024
    • TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2021-FEBRUARY 2024
  • 10.10 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    • FIGURE 44 EV/EBITDA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    • FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
  • 10.11 VALUATION AND FINANCIAL METRICS OF OLIGONUCLEOTIDE SYNTHESIS MARKET VENDORS (THERAPEUTIC APPLICATIONS)
    • FIGURE 46 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
    • FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)
  • 10.12 BRAND/PRODUCT COMPARATIVE ANALYSIS
    • 10.12.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH AND DIAGNOSTIC APPLICATIONS)
    • 10.12.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)

11 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 11.1 KEY PLAYERS
    • 11.1.1 DANAHER CORPORATION
    • TABLE 478 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 479 DANAHER CORPORATION: PRODUCTS OFFERED
    • TABLE 480 DANAHER CORPORATION: DEALS
    • TABLE 481 DANAHER CORPORATION: EXPANSIONS
    • TABLE 482 DANAHER CORPORATION: OTHER DEVELOPMENTS
    • 11.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
    • TABLE 485 THERMO FISHER SCIENTIFIC INC.: DEALS
    • 11.1.3 MERCK KGAA
    • TABLE 486 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT (2023)
    • TABLE 487 MERCK KGAA: PRODUCTS OFFERED
    • TABLE 488 MERCK KGAA: EXPANSIONS
    • 11.1.4 LGC LIMITED
    • TABLE 489 LGC LIMITED: COMPANY OVERVIEW
    • FIGURE 51 LGC LIMITED: COMPANY SNAPSHOT (2023)
    • TABLE 490 LGC LIMITED: PRODUCTS OFFERED
    • TABLE 491 LGC LIMITED: DEALS
    • TABLE 492 LGC LIMITED: EXPANSIONS
    • 11.1.5 EUROFINS SCIENTIFIC
    • TABLE 493 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)
    • TABLE 494 EUROFINS SCIENTIFIC: PRODUCTS OFFERED
    • TABLE 495 EUROFINS SCIENTIFIC: DEALS
    • 11.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 496 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 53 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 497 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
    • TABLE 498 AGILENT TECHNOLOGIES, INC.: EXPANSIONS
    • 11.1.7 KANEKA CORPORATION
    • TABLE 499 KANEKA CORPORATION: COMPANY OVERVIEW
    • FIGURE 54 KANEKA CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 500 KANEKA CORPORATION: PRODUCTS OFFERED
    • TABLE 501 KANEKA CORPORATION: EXPANSIONS
    • 11.1.8 MARAVAI LIFESCIENCES HOLDINGS, INC.
    • TABLE 502 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY OVERVIEW
    • FIGURE 55 MARAVAI LIFESCIENCES HOLDINGS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 503 MARAVAI LIFESCIENCES HOLDINGS, INC.: PRODUCTS OFFERED
    • TABLE 504 MARAVAI LIFESCIENCES HOLDINGS, INC.: DEALS
    • 11.1.9 AZENTA, INC.
    • TABLE 505 AZENTA, INC.: COMPANY OVERVIEW
    • FIGURE 56 AZENTA, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 506 AZENTA, INC.: PRODUCTS OFFERED
    • 11.1.10 TWIST BIOSCIENCE CORPORATION
    • TABLE 507 TWIST BIOSCIENCE CORPORATION: COMPANY OVERVIEW
    • FIGURE 57 TWIST BIOSCIENCE CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 508 TWIST BIOSCIENCE CORPORATION: PRODUCTS OFFERED
    • TABLE 509 TWIST BIOSCIENCE CORPORATION: DEALS
    • 11.1.11 GENSCRIPT BIOTECH CORPORATION
    • TABLE 510 GENSCRIPT BIOTECH CORPORATION: COMPANY OVERVIEW
    • FIGURE 58 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 511 GENSCRIPT BIOTECH CORPORATION: PRODUCTS OFFERED
    • TABLE 512 GENSCRIPT BIOTECH CORPORATION: EXPANSIONS
  • 11.2 KEY PLAYERS (THERAPEUTIC PRODUCTS)
    • 11.2.1 BIOGEN INC.
    • TABLE 513 BIOGEN INC.: COMPANY OVERVIEW
    • FIGURE 59 BIOGEN INC.: COMPANY SNAPSHOT (2023)
    • TABLE 514 BIOGEN INC.: PRODUCTS OFFERED
    • TABLE 515 BIOGEN INC.: PRODUCT APPROVALS
    • TABLE 516 BIOGEN INC.: DEALS
    • TABLE 517 BIOGEN INC.: EXPANSIONS
    • 11.2.2 ALNYLAM PHARMACEUTICALS, INC.
    • TABLE 518 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 60 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 519 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
    • TABLE 520 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS
    • TABLE 521 ALNYLAM PHARMACEUTICALS INC.: DEALS
    • 11.2.3 SAREPTA THERAPEUTICS, INC.
    • TABLE 522 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
    • FIGURE 61 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2023)
    • TABLE 523 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
    • TABLE 524 SAREPTA THERAPEUTICS: PRODUCT APPROVALS
    • TABLE 525 SAREPTA THERAPEUTICS: DEALS
    • TABLE 526 SAREPTA THERAPEUTICS: EXPANSIONS
    • 11.2.4 ASTRAZENECA
    • TABLE 527 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 62 ASTRAZENECA: COMPANY SNAPSHOT (2023)
    • TABLE 528 ASTRAZENECA: PRODUCTS OFFERED
    • TABLE 529 ASTRAZENECA: DEALS
    • TABLE 530 ASTRAZENECA: PRODUCT APPROVALS
    • 11.2.5 ASTELLAS PHARMA INC.
    • TABLE 531 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
    • FIGURE 63 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2022)
    • TABLE 532 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
    • TABLE 533 ASTELLAS PHARMA INC.: DEALS
    • TABLE 534 ASTELLAS PHARMA INC.: PRODUCT APPROVALS
    • 11.2.6 JAZZ PHARMACEUTICALS PLC
    • TABLE 535 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
    • FIGURE 64 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)
    • TABLE 536 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
    • 11.2.7 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
    • TABLE 537 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
    • FIGURE 65 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2022)
    • TABLE 538 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED
    • 11.2.8 IONIS PHARMACEUTICALS, INC.
    • TABLE 539 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 66 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 540 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
    • TABLE 541 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS
    • TABLE 542 IONIS PHARMACEUTICALS, INC.: DEALS
    • 11.2.9 NOVARTIS AG
    • TABLE 543 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 67 NOVARTIS AG: COMPANY SNAPSHOT (2023)
    • TABLE 544 NOVARTIS AG: PRODUCTS OFFERED
    • TABLE 545 NOVARTIS AG: PRODUCT APPROVALS
    • TABLE 546 NOVARTIS AG: DEALS
  • 11.3 OTHER PLAYERS
    • 11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
    • 11.3.2 BIOLEGIO BV
    • 11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
    • 11.3.4 BIOCOMMA LIMITED
    • 11.3.5 REVVITY, INC. (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
    • 11.3.6 BIO-SYNTHESIS, INC.
    • 11.3.7 CREATIVE BIOGENE
    • 11.3.8 REPROCELL, INC. (THROUGH SUBSIDIARY BIOSERVE)
  • *Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS